TYMS DPYD Polymorphism Screening for 5-FU Toxicity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting toxicity associated with 5-fluorouracil (FU) chemotherapy are unreliable, as commercially available kits fail to identify specific genetic variants that accurately predict adverse events, resulting in wide variability in patient responses and a lack of effective risk assessment.
Innovation Solution
A method involving the screening for specific polymorphisms in the TYMS and DPYD genes, such as rs45445694, rs16430, rs2612091, *2A, rs67376798, and rs7548189, to predict the risk of FU toxicity, providing up to 27% sensitivity and 91% specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If commercially available kits are used to predict FU toxicity, then the assay can be performed with standard reagents, but the prediction accuracy is unreliable and sensitivity is low
Solution Approach 1:
The patent changes the genetic parameters being tested by focusing on specific polymorphisms (DPYD *2A, 2846T>A, and TYMS variants) rather than using generic commercial kits. This targeted parameter selection improves both reliability and sensitivity by identifying the specific genetic markers most strongly associated with FU toxicity risk.
Solution Approach 2:
The patent segments the complex FU metabolism pathway into key functional components by testing specific polymorphisms in DPYD (degradation enzyme) and TYMS (target enzyme) genes. This segmentation allows focused analysis on the most critical determinants of toxicity rather than attempting to measure all metabolic parameters simultaneously.
2Reliability
If multiple genetic polymorphisms are screened, then prediction accuracy improves, but the complexity of the assay increases
Solution Approach 1:
The patent merges the assessment of multiple polymorphisms (DPYD *2A, 2846T>A, and TYMS variants) into a unified risk classification system. By combining these genetic markers and interpreting them together, the assay achieves high prediction accuracy while managing complexity through integrated analysis rather than separate independent tests.
Solution Approach 2:
The patent creates a universal risk assessment framework that can evaluate multiple polymorphisms using a consistent methodology. This multi-functional approach allows the same assay platform to screen for different genetic variants and provide comprehensive toxicity risk prediction, reducing overall system complexity through standardization.
3Loss of information
If clinical factors such as age and gender are considered, then some toxicity variability is explained, but a large portion of variability remains unexplained
Solution Approach 1:
The patent substitutes clinical demographic factors (age, gender) with molecular genetic markers (polymorphisms in DPYD and TYMS genes) to explain toxicity variability. This substitution moves from superficial clinical characteristics to underlying biological mechanisms, providing more reliable and actionable predictions despite the complexity of genetic interactions.
Data Source
AI summary
The invention provides an assay useful in predicting risk of 5-fluorouracil (FU) toxicity in a subject. The subject may be screened for the presence of at least one TYMS polymorphism and/or at least one DPYD polymorphism. Suitable TYMS and DPYD polymorphisms are provided. The presence of one or more of the polymorphisms indicates an increased risk of developing FU toxicity; a negative result may indicate a decreased risk of developing FU toxicity.